Acasti Pharma Inc.
13F holders, Q4 2025 (December 31)1holders −10
1new positions
0sold out
$0.00avg. 13F price*
At the end of Q4 2025, 1 institutions reported holding Acasti Pharma Inc. in their 13F filings, down 10 from Q3 2024. 1 opened new positions and 0 sold out. The largest holder was Motiv8 Investments LLC ($0).
- Company
- Acasti Pharma Inc.
- Filed as
- Grace Therapeutics Inc (Q4 2025)
- CUSIP
- 00430K865
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2025: 20 shares bought, net +20 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Motiv8 Investments LLC | 0.00% | New | 20 | $0 |
"% of holder's portfolio" is ACASTI PHARMA INC's weight in each manager's 13F, not the share of Acasti Pharma Inc. the manager owns.